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directly to consumers. In addition 
to testing for both the relatively 
common factor V Leiden gene mu-
tation and the uncommon gene 
for Canavan’s disease, these com-
panies provide tests as mundane 
as a cholesterol screening panel. 
But they serve only as a front end; 
federal regulations prohibit them 
from performing the tests them-
selves. The diagnostic laborato-
ries they use must be certified ac-
cording to the Clinical Laboratory 
Improvement Amendments, which 
specify that results must be re-
ported to the ordering clinician 
— not to the consumer. So each 
online testing company has an ar-
rangement with a physician whose 
name is used to order the tests and 
receive the results from the labs.
There are also numerous Inter-
net-based companies that market 
tests for ancestral origin or that 
determine whether two persons 
are related on the basis of poly-
merase-chain-reaction testing for 
variability in the Y chromosome 
or mitochondrial DNA. Some com-
panies also market noninvasive 
tests for fetal sex based on the 
analysis of fetal DNA in the ma-
ternal circulation, although one 
of these companies, Acu-Gen Bio-
lab of Massachusetts, is facing 
litigation stemming from testing 
inaccuracies.
Sharon Plon, chief of the Can-
cer Genetics Clinic at the Baylor 
College of Medicine in Houston, 
sums up the wariness of many 
physicians with regard to online 
genetic testing: “My biggest con-
cern,” she says, “is that members 
of the public are getting tests that 
they don’t understand, and their 
physicians may not understand, 
and they may be making big de-
cisions that are ill-informed.”
On July 27, 2006, the Federal 
Trade Commission issued a con-
sumer alert in an effort to address 
such concerns as well as privacy 
protection.
Dr. Wolfberg is a fellow in maternal fetal 
medicine at Tufts–New England Medical 
Center, Boston.
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“Who am I?” has always been a fundamental phil-
osophical question that may re-
quire decades of reflection to an-
swer. With the advent of DNA 
analysis, there is a growing pub-
lic impression that the answer may 
be found in our genes. Various In-
ternet sites offer descriptions of 
our ancestral history on the basis 
of our DNA, as well as testing for 
specific “disease genes” or gener-
al profiles that are used to rec-
ommend lifestyle changes, such 
as foods to be eaten or avoided. 
Researchers have even suggested 
that although the scientific evi-
dence is speculative and at best 
probabilistic, many people will 
want to have their DNA analyzed 
for markers of predispositions to-
ward certain behaviors, includ-
ing risk taking, overeating, ag-
gression, and even criminality.1,2
As these opportunities to learn 
about our DNA expand and affect 
the way we construct our personal 
identities, we should be alert to 
the risks as well as the benefits of 
exploring our DNA and basing an 
understanding of who we are on 
genetic testing. We should be wary 
of perceptions of ourselves — 
whether our own or others’ — that 
are based on results of tests that 
have not been validated or on mis-
interpretations of valid tests. We 
should be at least as concerned 
that others may know more than 
we do about our own genetic 
makeup. DNA analysis, in combi-
nation with the Internet, creates 
an unregulated market in DNA 
and new opportunities for inva-
sions of genetic privacy.
Using the Internet for the mar-
keting and purchasing of genetic 
tests sidesteps the doctor–patient 
relationship and eliminates mean-
ingful, face-to-face genetic coun-
seling. It also magnifies an older 
but unresolved danger: whenever 
identifiable DNA samples are col-
lected and stored, there is a high 
risk that violations of genetic pri-
vacy will follow. As the evolution 
of DNA banking for research dem-
onstrates, DNA donors shouldn’t 
assume that the privacy protec-
tions they take for granted in 
medical care and clinical research 
apply. People give up more than 
they realize when they hand over 
their DNA.
DNA collection and banking 
have already gone through two 
distinct stages. Initially, the peo-
ple most actively involved in DNA 
collection (outside law enforce-
ment and the U.S. military, both 
of which use DNA for identifica-
tion purposes only) were research-
ers seeking genetic markers for a 
particular disease, who typically 
collected DNA samples from fam-
ilies at risk for the disease of in-
terest and stored those samples. 
Consent forms typically contained 
a provision permitting the re-
searchers to retain and reanalyze 
DNA samples in related research 
after the primary study was com-
pleted. In the next iteration, con-
sent documents included much 
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broader statements in which sub-
jects acknowledged that their DNA 
samples would become the prop-
erty of the researchers (or insti-
tutions), who could control the 
samples for their own benefit. 
The research subject was thereby 
transformed into a DNA donor.3
Recent years have seen the 
emergence of private companies, 
such as the Ardais Corporation 
and DNA Sciences, that — either 
at hospitals or through appeals 
over the Internet — collect and 
analyze samples and personal in-
formation for the express purpose 
of selling them to researchers. 
The National Institutes of Health 
also has plans to develop a nation-
al repository similar to the U.K. 
Biobank, a new resource for re-
searchers that will eventually in-
clude information and blood sam-
ples from 500,000 volunteers. With 
such developments, DNA banking 
is quickly changing from an aca-
demic research activity to a gov-
ernmental and commercial enter-
prise conducted by DNA brokers. 
As a result, the relationship be-
tween subjects and researchers 
is being severed, and along with 
it the associated legal rights and 
obligations, including obligations 
to reduce risks to subjects’ privacy 
and to maintain the confidential-
ity of their information. The un-
resolved legal status of the rela-
tionships among donors, brokers, 
and researchers raises troubling 
questions about privacy and prop-
erty rights.
Without adequate protections 
for genetic privacy, autonomy to 
discover and use one’s own ge-
netic information for one’s own 
purposes cannot be realized. A 
fundamental concern is that the 
possession and storage of a per-
sonally identifiable DNA sample 
give the possessor access to a 
wealth of information about the 
person and his or her genetic rel-
atives. This includes information 
derivable from new DNA tests that 
were not available, or even antici-
pated, when the sample was re-
linquished. Consequently, as long 
as personally identifiable DNA 
samples are stored, there is the 
possibility of unauthorized access 
to and use of genetic information 
— an invasion of genetic privacy. 
To the extent that we see ourselves 
and our future as influenced by 
our genes, such invasions can dis-
rupt our very sense of self.4
In response to this concern, a 
majority of states have begun to 
regulate genetic testing and fair 
uses of genetic information. But 
these laws are almost exclusively 
antidiscrimination statutes that 
target the behavior of insurers, 
employers, or both after the DNA 
has been collected and analyzed. 
Some states, such as New Jersey, 
include broader privacy protec-
tions by prohibiting unconsented-
to collection and testing of DNA 
generally (although those statutes 
typically include broad exceptions 
for law enforcement and medical 
research) and by defining require-
ments for consent to testing. Only 
about half a dozen states, how-
ever, require either explicit con-
sent for sample storage or the 
destruction of samples after the 
purpose for their collection has 
been achieved.
It is, of course, the DNA sam-
ple itself, which can usefully be 
viewed as a coded probabilistic 
medical record, that makes genet-
ic privacy unique and differenti-
ates it from the privacy of medical 
records.5 The absence of any mean-
ingful property or privacy protec-
tion of DNA samples means that 
consumers must be extra cautious 
and seek specific information 
about the fate of the samples be-
fore sending them off for testing. 
Minimal information that they 
should obtain includes the site 
where the sample will be analyzed, 
whether and how long it will be 
stored, and who will have access 
to it and to any identifiable in-
formation linked to it. The best 
consumer advice, given current 
law, is that one should not send 
a DNA sample to anyone who does 
not guarantee to destroy it on 
completion of the specified test.
Redefining ourselves and our 
futures in accordance with in-
sights offered by our DNA is 
hopelessly reductionistic, if in-
herently fascinating. We will not 
learn who we are by having our 
DNA analyzed, but we will almost 
certainly give others the opportu-
nity to learn something about us. 
And our DNA is not like our cred-
it cards: we cannot simply get a 
new number. As long as someone 
has our identifiable DNA sample, 
he or she will be able to learn 
things about us we may not know, 
may not want to know, and cer-
tainly don’t want others to know. 
DNA collection, banking, and 
analysis are expanding rapidly, 
and we need a federal genetic 
privacy law to protect people who 
want to know what secrets their 
DNA contains, as well as those 
who don’t.
An interview with Prof. Annas can be heard 
at www.nejm.org. 
Ms. Roche and Mr. Annas are professors in 
the Department of Health Law, Bioethics, 
and Human Rights at Boston University 
School of Public Health, Boston.
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